{"id":194283,"name":"COHERUS BIOSCIENCES","slug":"coherus-biosciences","state":"CA","country":"United States of America","description":"Developer of biosimilar theraputics","totalSpending":1260000,"filings":24,"yearlySpending":[{"year":2018,"income":120000},{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":220000},{"year":2023,"income":200000}],"issues":["HCR","PHA"],"firms":["RED+BLUE STRATEGIES"],"lobbyists":["MELANIE NATHANSON","MEGAN MARSHALL"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Executive Office of the President (EOP)","Health & Human Services, Dept of (HHS)","Office of Management & Budget (OMB)","Centers For Medicare and Medicaid Services (CMS)"],"sampleDescriptions":["Issues related to the development of a healthy biosimilars marketplace in the United States.","Issues related to the development of a healthy biosimilars marketplace in the United States.","Executive and Legislative initiatives to allow the biosimilars market place to succeed in the United States.","Executive and Legislative initiatives to allow the biosimilars market place to succeed in the United States.","Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the Un"],"years":[2018,2019,2020,2021,2022,2023]}